Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer
January 11th 2017
Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.